Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 1Prostatic Neoplasms 1Neoplasms 1Multiple Myeloma 1Leukemia, Large Granular Lymphocytic 1

Interventions

Rituximab 3Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Etoposide 2Dasatinib 2tipifarnib 1siltuximab 1plerixafor 1fludarabine phosphate 1Tetradecanoylphorbol Acetate 1Tacrolimus 1Sunitinib 1Sirolimus 1Radiotherapy 1Radiation 1Prednisone 1Oxycodone 1Oxaliplatin 1Moxifloxacin 1Morphine 1Microarray Analysis 1Methadone 1Leukapheresis 1Lenalidomide 1Ipilimumab 1Interleukin-6 1Indium 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Fluorescent Antibody Technique 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Large Granular Lymphocytic × siltuximab × Clear all
NCT05316116 2026-02-05

Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Terminated
6 enrolled
Other hematologic neoplasm

Leukemia, Large Granular Lymphocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡